Good evening, you're tuned in to Markets Desk.
Palantir is turning heads on the earnings front, with the data analytics firm converting fifty-five cents of every revenue dollar into net profit last quarter. That's a net margin most software companies would envy, driven by a billion and sixty million in net income against one point nine four billion in revenue, signaling serious operational discipline.
Shifting to biotech, Moderna's mRNA cancer vaccine partnership with Merck is doing heavy lifting for the sector, pushing the IBB index toward recent highs. Eli Lilly and Natera are both drawing attention from technical analysts who see strong uptrends and potential breakout setups forming — a meaningful signal when the broader market is searching for leadership.
And over in income investing, the iShares Core Dividend Growth ETF is drawing fresh scrutiny for its two-gate screening process, which filters dividend stocks on both payout consistency and fundamental quality. In a rate environment where yield traps remain a real concern, that kind of disciplined methodology matters more than it might appear at first glance.
That's the tape. Markets Desk, signing off the floor.
